PARP inhibitor improves progression-free survival in patients with advanced breast cancers and BRCA
In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over ...
Dec 8, 2017